View Older Stories View More Recent Stories

Apr 5, 2021 08:30AM Genprex to Present at the 2021 Virtual Cell & Gene Meeting on the Mediterranean
Mar 30, 2021 08:32AM Genprex (GNPX) Announces Preclinical Data for TUSC2 Immunogene Therapy in Non-Small Cell Lung Cancer to Be Featured in Two Presentations at AACR
Mar 30, 2021 08:30AM Genprex Announces Preclinical Data for TUSC2 Immunogene Therapy in Non-Small Cell Lung Cancer to Be Featured in Two Presentations at the 2021 American Association for Cancer Research Annual Meeting
Mar 24, 2021 08:30AM Genprex to Present at the Spring 2021 Oncology Investor Conference on March 29
Mar 1, 2021 08:30AM Genprex to Participate in Upcoming March Investor Conferences
Feb 9, 2021 08:31AM Genprex (GNPX) Announces $25 Million Registered Direct Offering of Common Stock
Feb 9, 2021 08:30AM Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants
Feb 8, 2021 03:30PM Genprex Announces Formation of Clinical Advisory Board
Feb 4, 2021 08:30AM Genprex Recognizes World Cancer Day
Feb 1, 2021 01:33PM Genprex (GNPX) Issues Shareholder Update
Feb 1, 2021 01:30PM Genprex Issues Shareholder Letter and Provides Corporate Update
Jan 27, 2021 08:30AM Genprex to Present at the Virtual Investor Conference Small and Microcap Showcase on February 4
Jan 21, 2021 08:30AM Genprex to Present its Cutting-Edge Gene Therapies at the MoneyShow Accredited Investors Virtual Expo
Jan 14, 2021 08:30AM Genprex to Present at NobleCon17 on January 19
Jan 13, 2021 09:00AM Genprex Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer
Dec 24, 2020 01:02PM Genprex, Inc. Announces Closing Of $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Without Warrants
Dec 22, 2020 01:15PM Genprex (GNPX) Announces $12 Million Registered Direct Offering of Common Stock
Dec 22, 2020 01:15PM Genprex, Inc. Announces $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules, Without Warrants
Dec 22, 2020 09:32AM Genprex Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer
Dec 8, 2020 08:16AM Genprex Completes Manufacturing Technology Transfer for Novel Gene Therapy
Dec 3, 2020 08:17AM Genprex to Present at the Benzinga Global Small Cap Conference on December 8
Nov 30, 2020 02:05PM Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer
Nov 24, 2020 08:16AM Genprex to Participate at the Diamond Equity Research Emerging Growth Invitational on December 1
Nov 11, 2020 08:16AM Genprex to Participate in Panel at Life Sciences Summit on November 17
Nov 10, 2020 08:17AM Genprex Strengthens Scientific Advisory Board with Appointment of Lead Researcher of University of Pittsburgh, George K. Gittes, MD
Oct 30, 2020 08:17AM Genprex Unveils New Branding for Upcoming Combination Clinical Trials in Non-Small Cell Lung Cancer
Oct 29, 2020 08:20AM Genprex (GNPX) Receives Conditional FDA Acceptance of Proprietary Name REQORSA for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer
Oct 29, 2020 08:16AM Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA™ for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer
Oct 26, 2020 08:16AM Genprex Promotes Eric Chapdelaine to Vice President of Manufacturing
Oct 7, 2020 08:17AM Genprex to Present at Zooming with LD Micro on October 14, 2020
Oct 6, 2020 08:16AM Genprex to Present at the Alliance for Regenerative Medicine’s Virtual Cell and Gene Meeting on the Mesa
Sep 21, 2020 08:17AM Genprex Names Seasoned IP Executive, Thomas C. Gallagher, as Senior Vice President of Intellectual Property and Licensing
Sep 2, 2020 08:17AM Genprex Appoints William E. Gannon, Jr., MD, MBA, as Vice President of Regulatory Affairs
Aug 26, 2020 08:17AM Genprex to Present at The LD 500 Virtual Conference
Aug 26, 2020 08:17AM Genprex to Present at The LD 500 Virtual Conference
Jul 31, 2020 08:17AM Genprex to Present at Proactive’s One2One Virtual Investor Forum on August 4, 2020
Jul 30, 2020 08:16AM Genprex CEO Participates in a Second-Round Live Interview on the “Big Biz Show”
Jul 21, 2020 08:17AM National Institutes of Health (NIH) Awards Research Grant of $2.59 Million to University of Pittsburgh for Diabetes Gene Therapy Technology Licensed by Genprex
Jun 29, 2020 08:16AM Genprex Added to Russell 3000® Index
Jun 25, 2020 08:18AM Genprex (GNPX) Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate
Jun 25, 2020 08:17AM Genprex Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate
Jun 24, 2020 08:16AM Genprex CEO to Interview Live on “The Big Biz Show”
Jun 16, 2020 08:17AM Genprex Expands Manufacturing Program with Aldevron to Advance Oncoprex™ Clinical Development
Jun 9, 2020 08:17AM Genprex Scheduled to Join Russell 3000® Index
Jun 8, 2020 08:17AM Genprex to Present at the MoneyShow June Virtual Event
May 28, 2020 08:17AM Genprex (GNPX) Announces Receipt of $2.5 Million in Cash from Recent Warrant Exercises
May 28, 2020 08:17AM Genprex Announces Receipt of $2.5 Million in Cash from Recent Warrant Exercises
May 5, 2020 08:59AM Genprex (GNPX) Surges After Entering License Agreement with MD Anderson for its TUSC2 Gene Therapy Combo
May 5, 2020 08:17AM Genprex Enters Into Exclusive Worldwide Patent and Technology License Agreement for Combination of its TUSC2 Gene Therapy with Immunotherapies
May 4, 2020 08:17AM Genprex Issues April 2020 Shareholder Letter
View More Recent Stories View Older Stories